But the key is smart, personalized usenot blind experimentation
A 2018 review described BPC-157 in relation to standard angiogenic growth factors, discussing tendon, ligament and bone healing models and angiogenic effects
Manfredi Rizzo is former Director, Clinical Medical & Regulatory Department, Novo Nordisk Europe East and South and has given lectures, received honoraria and research support, and participated in conferences, advisory boards and clinical trials sponsored by pharmaceutical industry including Amgen, AstraZeneca, Boehringer Ingelheim, Kowa, Eli Lilly, Meda, Mylan, Merck Sharp & Dohme, Novo Nordisk, Novartis, Roche Diagnostics, Sanofi and Servier
The dosage of Wegovy is always determined by a doctor